• GSK’s majority-owned ViiV Healthcare will present findings linking Vocabria with Rekambys to better adherence than daily oral HIV therapy at HIV Glasgow.
• The US real-world study also found patients receiving the injectable regimen were more likely to remain on treatment.
• Pipeline findings support further evaluation of investigational HIV treatments VH184 and VH499 for potential twice-yearly dosing; neither is approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611091000BIZWIRE_USPR_____20261109_BW813778) on November 09, 2026, and is solely responsible for the information contained therein.